Background
==========

Similar to cardiac surgery patients, medical--surgical critically ill patients may benefit from avoiding hyperglycemia. Our objective was to evaluate the feasibility of a randomized trial of target glucose ranges 5--7 mmol/l or 8--10 mmol/l.

Setting
=======

A 15-bed medical--surgical ICU.

Methods
=======

We randomized patients ages \>18 years if they were expected to be in the ICU for \>72 hours and had serum glucose \>10 mmol/l. Patients were excluded if they had diabetic ketoacidosis, hypoglycemia, liver disease, or were palliative. Patients had concealed allocation to a target glucose range of 5--7 mmol/l or 8--10 mmol/l. Arterial catheters were used for sampling. Dedicated glucometers were calibrated daily to the laboratory measurement. We used enteral nutrition as early as possible; total parenteral nutrition was used in five patients. Insulin SC and oral hypoglycemic agents were prohibited. We mixed 50 U Humulin R in 50 ml 0.9% NaCl and began infusions at 0.5 U/hour; infusions were titrated according to pretested algorithms. Preceding this pilot was a survey of ICU staff, a glucometer reliability study, and a multidisciplinary educational program.

Results
=======

The feasibility sample size was 20 patients. The APACHE II score was 32 (10.2); 14 were insulin-dependent pre-ICU, and all 20 patients were medical admissions. A total of 758 of 1607 values (47.2%) were in the 5--7 mmol/l range, and 256 of 660 values (40.2%) were in the 8--10 mmol/l range. Glucose \< 2.5 mmol/l developed nine times; treatment included 0.5 A 50 g dextrose/100 ml H~2~O on six occasions and stopping the insulin infusion in each case. No adverse consequences were observed.

Conclusions
===========

In ICU patients with high illness severity, glucose values were in two target ranges most of the time, using well-accepted initiation and maintenance insulin infusion algorithms. A large randomized trial of glycemic control is feasible in this population, examining clinically important outcomes. However, this will require more intensive measures to achieve target values.
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